About This Reference Desk

What Peptide Care Now is

Peptide Care Now is an independent editorial reference desk covering the published research on two peptides studied for immune modulation and thymic biology: thymulin and thymosin alpha-1. The site exists to make a scattered, technically dense, and frequently misrepresented literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which species and models, and how far that evidence reaches.

The organizing idea is precision over breadth. Rather than catalogue dozens of immune-related peptides superficially, this desk goes deep on two compounds that map the thymus-to-immune-system axis from complementary angles — thymulin as the hormonal zinc-dependent signal the thymus itself produces, and thymosin alpha-1 as the broader immunomodulatory peptide with a substantial, honest, and at times humbling clinical record. Each compound has its own page; a comparison page lines them up side by side; and a single shared references list aggregates every source.

How it is compiled

Three principles govern what appears on this site.

First, everything is anchored to the peer-reviewed literature. Every research claim is tied to a numbered citation — PubMed-indexed journal articles, clinical trial reports, and systematic reviews — collected on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such. Effect sizes, trial populations, species, and routes of administration are described as they appear in the source paper, not smoothed into generic claims.

Second, the evidence is reported at its true strength. Doses are described in the species and route in which they were studied — never scaled to humans or offered as a recommendation. Where a trial returned a null result, that result is presented prominently, not buried. The 2025 Phase 3 TESTS null result for thymosin alpha-1 in sepsis is not a footnote on this site; it is a section heading ^[8].

Third, the pages are cross-referenced. Because thymulin and thymosin alpha-1 both relate to thymic output and T-cell biology, the pages link to one another so a reader can follow a shared concept — T-lymphocyte differentiation, neuroendocrine modulation — across both compounds and track where the stories converge and where they are wholly distinct.

What it is not

Peptide Care Now is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person, and it never frames an animal-study dose as something a human should take.

The peptides discussed here are research compounds. Neither is FDA-approved for systemic human use in the United States; thymosin alpha-1 is approved abroad under the brand name thymalfasin, but those approvals cover specific clinical indications with specific dosing labels managed by licensed clinicians in those jurisdictions. Readers who believe they may benefit from immune-modulating therapies should consult a licensed clinician working with regulated, evidence-based options within their own jurisdiction. The value this site offers is a calm, data-forward map of the literature — nothing more.